RVV — Revive Therapeutics Share News
0.000.00%
Last trade - 00:00- CA$8.71m
- CA$8.71m
Brief: Revive Therapeutics Provides Update Of Phase 3 Clinical Study For Bucillamine In The Treatment Of Covid-19
Brief: Revive Therapeutics Says First Patient Enrolled For Psilocybin Clinical Study For Methamphetamine Use Disorder
Brief: Revive Therapeutics Submits Updated Briefing Package
Brief: Revive Therapeutics Announces Publication Showing Bucillamine’S Potential Impact On Covid-19 Omicron Variants
Brief: Revive Therapeutics Announces FDA Recommendation For Type C Meeting To Discuss Amended Protocol Agreement Of Phase 3 Clinical Study For Bucillamine In The Treatment Of Covid-19
Brief: Revive Therapeutics Provides Update On Phase 3 Clinical Trial For Bucillamine In Covid-19
Brief: Revive Therapeutics Provides Update On The Psilocybin Clinical Study For Methamphetamine Use Disorder And Oral Psilocybin Thin Film Strip Program
Brief: Revive Therapeutics Announces Submission Of Amended Phase 3 Covid-19 Study Protocol To FDA
Brief: Revive Therapeutics Provides Update On Phase 3 Clinical Trial For Bucillamine In Covid-19
Brief: Revive Therapeutics Provides Update On Phase 3 Clinical Trial For Bucillamine In Covid-19
Brief: Revive Therapeutics Provides Update On Phase 3 Clinical Trial For Bucillamine In Covid-19
Brief: Revive Therapeutics Provides Update On Phase 3 Clinical Trial For Bucillamine In Covid-19
Brief: Revive Therapeutics Provides Update On Phase 3 Clinical Trial For Bucillamine In Covid-19
Brief: Revive Provides Update On Phase 3 Clinical Trial For Bucillamine In COVID-19
Brief: Revive Therapeutics Receives FDA Orphan Drug Designation For Liver Medication
Brief: Revive Therapeutics Provides Update Of Psilocybin Pharmaceutical Programs
Brief: Revive Therapeutics Clarifies Status Of Its Phase 3 Clinical Trial For Bucillamine In Covid-19
Brief: Revive Therapeutics Provides Update On Phase 3 Clinical Trial For Bucillamine In COVID-19
Brief: Revive Therapeutics Expands Bucillamine Research To Treat Omicron Variant And Adds Inflammatory Markers To FDA Phase 3 Clinical Trial